Megan M Lo, MD
Disclosures: NO DISCLOSURE

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person.  DO NOT EXCEED FIVE PAGES.

NAME: Megan M. Lo

eRA COMMONS USER NAME (credential, e.g., agency login): mlo

POSITION TITLE: Assistant Professor

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

 

Completion Date

MM/YYYY

 

FIELD OF STUDY

 

  1. Yale University.  New Haven, CT.

B.S.

06/2000

Molecular Biophysics and Biochemistry

 

  1. University of Massachusetts Medical School.  Worcester, MA.

 

  1. Maine Medical Center.  Portland, ME.

 

  1. Cincinnati Children’s Hospital and Medical Center.  Division of Nephrology and HypertensionCincinnati, OH.

 

  1. University of Cincinnati, College of Medicine, Division of Epidemiology and Biostatistics.  Cincinnati, OH.

 

M.D.

 

 

 

 

 

 

 

 

M.S.

 

06/2005

 

 

06/2008

 

06/2011

 

 

 

06/2011

 

 

 

 

 

Medicine

 

 

Pediatrics Residency

 

Pediatric Nephrology Fellowship

 

 

Clinical and Translational Research

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  1. Personal Statement
    I have always known I am a Clinician at heart.  However I also thoroughly believe that we should learn from every patient encounter whether it be personal gain of experience or structured data gathering and synthesis.  In this age of EMR’s, my ideal research environment would be centralized banks of anonymous patient data compiled, regardless of source of EMR brand, that can be queried, compared, and learned from.  Trials can then be made based on differences in outcome from different styles of practice, as well as testing individual patient histories against the population to search for which management strategy would be most likely to benefit that patient.

In the absence of such a system currently, I work with my colleagues within my own institution, as well as around the country and the world, to improve the lives of our patients.  My main passion is regarding nephrotic syndrome, but the reason I went into Pediatric Nephrology specifically was the emphasis on total patient care, not just our particular organ system.  Therefore, I also wish to reduce morbidity caused by acute kidney injury from other therapies such as chemotherapy or antibiotics, and improve long-term quality of life for our pediatric patients into adulthood.

In Pediatrics overall, and especially in Nephrology, adequate patient numbers are often a concern.  I therefore am involved in studies which collaborate with other Divisions and programs to attain adequate power.  This increases the complexity of running these studies, and so my third goal is reducing barriers in these collaborations while maintaining study integrity.

 

B.              Positions and Honors

  • “High Evaluation” Teaching Award for M3 Pediatric Clerkship, 2014-2015 academic year.
  • Housestaff Teaching Award 2013.
  • 2018 - current: Member, Audit Committee, American Society of Pediatric Nephrology.
  • 10/2017 – current: Member, Website Committee, Midwest Pediatric Nephrology Consortium.
  • 10/2017 – current: Member, working group to establish common IRB for studies through the Midwest Pediatric Nephrology Consortium.

 

 

C.              Contributions to Science

              Current research / projects:

  1. Clear the Methotrexate, Save the Kidneys: A Reduced Volume Hydration Protocol to Improve High Dose Methotrexate Clearance in Children with Cancer, initial planning phase, sub-I.
  2. Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber LA-15 System, site PI.
  3. An Open-Label, Randomized, Parallel Group Study to Asses the Safety and Efficacy of Hectorol (doxercalciferol capsules) in Pediatric Patients with Chronic Kidney Disease Stages 3 and 4 with Secondary Hyperparathyroidism Not Yet on Dialysis, site PI.
  4. Childhood Nephrotic Syndrome Observational Study – multi-center collaborative of the Midwest Pediatric Nephrology Consortium, site PI.
  5. ATLANTIS: A Trial of ACTH in Nephrotic Syndrome – multi-center collaborative of the Midwest Pediatric Nephrology Consortium, site PI.
  6. 4/15-1/16/16: Hosted Spring 2016 meeting of the Midwest Pediatric Nephrology Consortium.

 

Publications:

11. Kaspar CDW, Lo M, Bunchman TE, Xiao N.  “The antenatal urinary tract dilation classification system accurately predicts severity of kidney and urinary tract abnormalities.” Journal of Pediatric Urology 2017 Oct; 13(5): 485.e1-485.e7.

10. Kaspar C, Bunchman TE, Lo M, Hoffmann S, Ozen S, Sanderson K, Verghese P, Kidd J. “Nephrology and Rheumatology Practice Patterns in Pediatric Granulomatosis with Polyangiitis: a Midwest Pediatric Nephrology Consortium (MWPNC) Study”. Poster presentation to the 2017 American Society of Pediatric Nephrology Meeting, 2703598, May 2017.

9. Bunchman TE, Lo MM. Chronic Kidney Disease, Pediatric (Renal Failure, Chronic). In: Andriole GL, Burnett, AL, Flanigan RC, et al, editors. The 5-Minute Urology Consult, 3rd Ed. Philadelphia: Wolters Kluwer; 2015. p. 96-87.

8. Lo MM, Bunchman TE. Hemodialysis and Continuous Renal Replacement Therapy.  In: Chishti AS, Alam S, KiesslingSG, editors. Kidney and Urinary Tract Diseases in the Newborn. eBook: Springer; 2014. p. 307-320.

7. M Lo, S Salisbury, P Scherer, S Furth, B Warady, M Mitsnefes. “Serum adiponectin complexes and cardiovascular risk in children with chronic kidney disease.Pediatr Nephrol 2011 Nov; 26(11): 2009-17.

6. M Lo, M Mitsnefes. “Adiponectin, cardiovascular disease, chronic kidney disease: emerging data on complex interactions.Pediatr Nephrol 2011 Feb 21 [Epub ahead of print].

5. M Lo, M Bennett, and P Devarajan. “Serum Proteomics for Biomarkers of FSGS Recurrence Post-Transplant”. Poster presentation to the 43rd Annual Meeting and Scientific Exposition of the American Society of Nephrology, SA−PO2208, November 2010.

4. M Lo, S Salisbury, S Furth, B Warady and M Mitsnefes.  “Predictors of Adiponectin in CKiD”. Poster presentation to “15th Congress of the International Pediatric Nephrology Association”, August 2010.

3. M Lo, S Furth, B Warady and M Mitsnefes.  “Low-Molecular Weight Adiponectin is Associated with Left Ventricular Mass Index”. Accepted as poster to “15th Congress of the International Pediatric Nephrology Association”, 8/2010.

2. MM Lo, JQ Mo, BP Dixon, and K Czech. “Disseminated histoplasmosis associated with hemophagocytic lymphohistiocytosis in kidney transplant recipients.”  American Journal of Transplantation 2010 Mar; 10(3): 687-691.

1. GM Kelly, M Lo, and S Hockfield. “The hyaluronan-binding fragment of BEHAB is a component of perineuronal nets.” Society for Neuroscience 29th Annual Meeting, poster presentation. 10/1999: 412.6.

 

 

D.              Additional Information: Research Support and/or Scholastic Performance